KeyCorp reaffirmed their buy rating on shares of Teladoc (NYSE:TDOC) in a research note released on Wednesday morning. The firm currently has a $41.00 target price on the health services provider’s stock. KeyCorp also issued estimates for Teladoc’s Q4 2017 earnings at ($0.31) EPS, FY2017 earnings at ($1.46) EPS, Q1 2018 earnings at ($0.36) EPS, Q2 2018 earnings at ($0.19) EPS, Q3 2018 earnings at ($0.18) EPS, Q4 2018 earnings at ($0.20) EPS, FY2018 earnings at ($0.93) EPS and FY2019 earnings at ($0.75) EPS.
A number of other equities analysts have also recently issued reports on TDOC. Robert W. Baird cut Teladoc from an outperform rating to a neutral rating and increased their price target for the stock from $14.00 to $36.00 in a report on Monday, September 18th. Zacks Investment Research raised Teladoc from a sell rating to a hold rating in a research report on Thursday, September 21st. Cantor Fitzgerald reaffirmed a hold rating and set a $31.00 target price on shares of Teladoc in a research report on Tuesday, September 26th. Piper Jaffray Companies reaffirmed a buy rating and set a $42.00 target price on shares of Teladoc in a research report on Friday, September 29th. Finally, Cowen reaffirmed an outperform rating and set a $39.00 target price on shares of Teladoc in a research report on Saturday, September 30th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $39.31.
Teladoc (NYSE:TDOC) traded down $0.55 during trading on Wednesday, hitting $32.65. The company’s stock had a trading volume of 1,905,336 shares, compared to its average volume of 1,170,000. The company has a market cap of $1,980.00 and a PE ratio of -22.52. Teladoc has a 52-week low of $15.65 and a 52-week high of $38.40. The company has a debt-to-equity ratio of 0.83, a current ratio of 5.08 and a quick ratio of 5.08.
In related news, CEO Jason N. Gorevic sold 100,000 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $32.99, for a total value of $3,299,000.00. Following the completion of the sale, the chief executive officer now directly owns 718,261 shares of the company’s stock, valued at approximately $23,695,430.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Mark Hirschhorn sold 25,000 shares of the stock in a transaction on Monday, October 16th. The shares were sold at an average price of $32.37, for a total value of $809,250.00. Following the completion of the sale, the chief financial officer now directly owns 20,887 shares of the company’s stock, valued at $676,112.19. The disclosure for this sale can be found here. Insiders sold a total of 210,000 shares of company stock valued at $6,889,350 over the last three months. 4.47% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ETF Managers Group LLC purchased a new stake in Teladoc in the 2nd quarter valued at $104,000. Pacad Investment Ltd. purchased a new stake in Teladoc in the 2nd quarter valued at $135,000. Fred Alger Management Inc. purchased a new stake in Teladoc in the 2nd quarter valued at $139,000. Ameritas Investment Partners Inc. raised its position in Teladoc by 134.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,724 shares of the health services provider’s stock valued at $164,000 after buying an additional 2,707 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. purchased a new stake in Teladoc in the 2nd quarter valued at $166,000.
Teladoc Company Profile
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with our FREE daily email newsletter.